⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SVRA News
Savara Inc.
Savara Announces Participation in the H.C. Wainwright & Co. 4 th Annual BioConnect Investor Conference
businesswire.com
SVRA
Savara Announces New Employment Inducement Grant
businesswire.com
SVRA
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
businesswire.com
SVRA
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
businesswire.com
SVRA
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
businesswire.com
SVRA
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
businesswire.com
SVRA
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
businesswire.com
SVRA
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
businesswire.com
SVRA
Form 8-K
sec.gov
SVRA
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
businesswire.com
SVRA